Phase 4 N=250 The Treatment of Glabellar Frown Lines
Glabellar Frown Lines
Primary: Efficacy, Measured as the Percentage of Participants Who Responded to Treatment — 95.7; 99.2 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=391 A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides
Forehead Rhytides · Glabellar Rhytides
Primary: Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at…
N/A N=175 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
Facial Rhytides · Glabellar Frown Lines
Primary: Percentage of Participants Achieving a Score of None or Mild by Investigator-Assessed Facial Wrinkle Scale With Photonumeric Guide (FWS) in Forehead Lines at Maximum…
Phase 3 N=234 MT10109L in the Treatment of Glabellar Lines
Glabellar Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND…
Phase 2 N=42 Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
Glabellar Frown Lines (GL)
Primary: Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS). — 1; 0; 0; 2 Participants
Phase 3 N=902 Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
Glabellar Lines · Lateral Canthal Lines
Primary: Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown — 769 Participants
Phase 4 N=50 Botox Cosmetic and the Young Patient With Glabellar Furrows
Glabellar Furrows
Primary: Reduction of the Facial Wrinkle Scale — 1.86; 2.10 units on a scale — p=<.001
Phase 3 N=271 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
Moderate to Severe Glabellar Frown Lines
Primary: Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's…
Phase 2 N=198 AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
Glabellar Lines
Primary: Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7…
Phase 3 N=190 Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
Glabellar Lines
Primary: The Percentage of Responders at Day 29 Cycle 1 as Measured by Investigator's Live Assessment (ILA) of Glabellar Lines at Maximum Frown: DB Period — 81.6; 0.8 Adjusted…
Phase 3 N=415 MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
Glabellar Lines · Lateral Canthal Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) — 0; 78; 66 Participants
Phase 3 N=787 A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
Facial Rhytides · Glabellar Rhytides
Primary: Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at…
N/A N=143 Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
Cosmetic Techniques
Primary: the Change in Dynamic Strain in the Glabella Area After Injection Over Time — 6.4; 10.9; 6.6; 8.9 percent difference of neutral+dyanamic
Phase 4 N=185 Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
Glabellar Rhytides
Primary: Percentage of Subjects With a ≥ 1-Grade Improvement From Day 1 in the Investigator Assessed Facial Wrinkle Scale of Glabellar Rhytides at Maximum Contraction — 97.1…
Phase 3 N=276 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
Moderate to Severe Glabellar Frown Lines
Primary: Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's…
Phase 3 N=300 Treatment of Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown at One Month. — 165; 0…
Phase 2 N=399 Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
Glabellar Frown Lines
Primary: Number of Composite Responders at Month 1 — 64; 71; 72; 77 Participants
Phase 4 N=224 Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
Glabellar Lines
Primary: Number of Subjects With a Treatment Response at Day 28 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the Facial…
Phase 3 N=306 Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 74.0; 1.0 percentage of responders
Phase 3 N=303 Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 73.6; 0 percentage of subjects
Phase 3 N=324 A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
Glabellar Frown Lines
Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 70.4; 1.3 percentage of…
Phase 3 N=185 Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
Moderate to Severe Glabellar Lines
Primary: The Proportion of Responders at Day 29 in the ILA of Glabellar Lines at Maximum Frown. — 88.3; 1.4 Adjusted percentage of responders — p=<0.0001
Phase 3 N=638 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Glabellar Lines
Primary: Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar…
Phase 3 N=330 A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
Glabellar Frown Lines
Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 67.5; 1.2 percentage of…
Phase 3 N=368 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 49.5 percentage of subjects — p=<0.0001
Phase 3 N=801 Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
Glabellar Lines
Primary: Incidence of Adverse Events (AEs) — 374 Participants
Phase 3 N=362 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 52.3 percentage of subjects — p=<0.0001
N/A N=40 Photographic Assessment of Eyebrow Position and Range of Motion
Brow Ptosis
Primary: Eyebrow Position — -3.22 mm
Phase 3 N=309 A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
Glabellar Lines
Primary: Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar…
Phase 2 N=30 Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles
Wrinkles
Primary: Severity of the Forehead Wrinkles by the Evaluator at Maximum Contraction and at Rest Using the Forehead Wrinkles Severity Scale (0 to 3) at Each Study Visit and for…